Neuroprotection of the Inner Retina Also Prevents Secondary Outer Retinal Pathology in a Mouse Model of Glaucoma

• Published in: Investigative ophthalmology & visual science Vol. 62; no. 9; p. 35
• Main Authors: Kumar, Sandeep, Ramakrishnan, Hariharasubramanian, Viswanathan, Suresh, Akopian, Abram, Bloomfield, Stewart A
• Format: Journal Article
• Language: English
• Published: United States The Association for Research in Vision and Ophthalmology 01.07.2021
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Disease Models, Animal; Electroretinography; Glaucoma; Glaucoma - pathology; Glaucoma - physiopathology; Glaucoma - prevention & control; Immunohistochemistry; Injections; Intraocular Pressure - physiology; Meclofenamic Acid - administration & dosage; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Neuroprotection - physiology; Retinal Photoreceptor Cell Inner Segment - drug effects; Retinal Photoreceptor Cell Inner Segment - metabolism; Retinal Photoreceptor Cell Inner Segment - ultrastructure
• ISSN: 1552-5783; 0146-0404; 1552-5783
• DOI: 10.1167/iovs.62.9.35

We examined structural and functional changes in the outer retina of a mouse model of glaucoma. We examined whether these changes are a secondary consequence of damage in the inner retina and whether neuroprotection of the inner retina also prevents outer retinal changes. We used an established microbead occlusion model of glaucoma whereby intraocular pressure (IOP) was elevated. Specific antibodies were used to label rod and cone bipolar cells (BCs), horizontal cells (HCs), and retinal ganglion cells (RGCs), as well as synaptic components in control and glaucomatous eyes, to assess structural damage and cell loss. ERG recordings were made to assess outer retina function. We found structural and functional damage of BCs, including significant cell loss and dendritic/axonal remodeling of HCs, following IOP elevation. The first significant loss of both BCs occurred at 4 to 5 weeks after microbead injection. However, early changes in the dendritic structure of RGCs were observed at 3 weeks, but significant changes in the rod BC axon terminal structure were not seen until 4 weeks. We found that protection of inner retinal neurons in glaucomatous eyes by pharmacological blockade of gap junctions or genetic ablation of connexin 36 largely prevented outer retinal damage. Together, our results indicate that outer retinal impairments in glaucoma are a secondary sequalae of primary damage in the inner retina. The finding that neuroprotection of the inner retina can also prevent outer retinal damage has important implications with regard to the targets for effective neuroprotective therapy.